ArticleJournal of hematology & oncology2017

Prognostic and therapeutic value of disruptor of telomeric silencing-1-like (DOT1L) expression in patients with ovarian cancer.

Xiaoxue Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.